Jerel Davis - 25 Jul 2023 Form 4 Insider Report for Turnstone Biologics Corp. (TSBX)

Signature
/s/ P. Joseph Campisi, Jr., Attorney-in-Fact
Issuer symbol
TSBX
Transactions as of
25 Jul 2023
Transactions value $
$2,700,000
Form type
4
Filing time
27 Jul 2023, 16:21:36 UTC
Previous filing
20 Jul 2023
Next filing
11 Aug 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSBX Common Stock Conversion of derivative security +2,528,864 2,528,864 25 Jul 2023 By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Common Stock Conversion of derivative security +192,458 192,458 25 Jul 2023 By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Common Stock Conversion of derivative security +84,313 84,313 25 Jul 2023 By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Common Stock Conversion of derivative security +76,067 76,067 25 Jul 2023 By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Common Stock Conversion of derivative security +274,990 274,990 25 Jul 2023 By Versant Vantage II, L.P. F1, F6
transaction TSBX Common Stock Purchase $2,369,496 +197,458 +7.81% $12.00 2,726,322 25 Jul 2023 By Versant Venture Capital V, L.P. F2
transaction TSBX Common Stock Purchase $180,336 +15,028 +7.81% $12.00 207,486 25 Jul 2023 By Versant Venture Capital V (Canada) LP F3
transaction TSBX Common Stock Purchase $78,900 +6,575 +7.8% $12.00 90,888 25 Jul 2023 By Versant Ophthalmic Affiliates Fund I, L.P. F4
transaction TSBX Common Stock Purchase $71,268 +5,939 +7.81% $12.00 82,006 25 Jul 2023 By Versant Affiliates Fund V, L.P. F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSBX Series A Preferred Stock Conversion of derivative security $0 -7,897,999 -100% $0.000000* 0 25 Jul 2023 Common Stock 988,832 By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Series A Preferred Stock Conversion of derivative security $0 -601,077 -100% $0.000000* 0 25 Jul 2023 Common Stock 75,255 By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Series A Preferred Stock Conversion of derivative security $0 -263,349 -100% $0.000000* 0 25 Jul 2023 Common Stock 32,971 By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Series A Preferred Stock Conversion of derivative security $0 -237,575 -100% $0.000000* 0 25 Jul 2023 Common Stock 29,744 By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security $0 -3,530,789 -100% $0.000000* 0 25 Jul 2023 Common Stock 442,055 By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security $0 -268,711 -100% $0.000000* 0 25 Jul 2023 Common Stock 33,642 By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security $0 -117,730 -100% $0.000000* 0 25 Jul 2023 Common Stock 14,739 By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Series B-1 Preferred Stock Conversion of derivative security $0 -106,208 -100% $0.000000* 0 25 Jul 2023 Common Stock 13,297 By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security $0 -7,650,043 -100% $0.000000* 0 25 Jul 2023 Common Stock 957,787 By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security $0 -582,206 -100% $0.000000* 0 25 Jul 2023 Common Stock 72,892 By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security $0 -255,081 -100% $0.000000* 0 25 Jul 2023 Common Stock 31,936 By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Series B-2 Preferred Stock Conversion of derivative security $0 -230,117 -100% $0.000000* 0 25 Jul 2023 Common Stock 28,810 By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Series C Preferred Stock Conversion of derivative security $0 -1,119,729 -100% $0.000000* 0 25 Jul 2023 Common Stock 140,190 By Versant Venture Capital V, L.P. F1, F2
transaction TSBX Series C Preferred Stock Conversion of derivative security $0 -85,217 -100% $0.000000* 0 25 Jul 2023 Common Stock 10,669 By Versant Venture Capital V (Canada) LP F1, F3
transaction TSBX Series C Preferred Stock Conversion of derivative security $0 -37,283 -100% $0.000000* 0 25 Jul 2023 Common Stock 4,667 By Versant Ophthalmic Affiliates Fund I, L.P. F1, F4
transaction TSBX Series C Preferred Stock Conversion of derivative security $0 -33,682 -100% $0.000000* 0 25 Jul 2023 Common Stock 4,216 By Versant Affiliates Fund V, L.P. F1, F5
transaction TSBX Series D Preferred Stock Conversion of derivative security $0 -2,196,402 -100% $0.000000* 0 25 Jul 2023 Common Stock 274,990 By Versant Vantage II, L.P. F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series, Series B-2 Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically convert into shares of Common Stock on a 7.9872 for 1 basis immediately prior to the closing of the Issuer's initial public offering for no additional consideration and had no expiration date.
F2 Shares are held by Versant Venture Capital V, L.P. ("Versant V"). Versant Ventures V, LLC ("Versant V GP") is the sole general partner of Versant V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Versant V. The Reporting Persons disclaims beneficial ownership of the shares held by Versant V, except to the extent of his respective pecuniary interest therein.
F3 Shares are held by Versant Venture Capital V (Canada) LP ("Canada V"). Versant Ventures V (Canada), L.P. ("Canada V GP") is the general partner of Canada V and Versant Ventures V GP-GP (Canada), Inc. ("Canada V GP-GP") is the sole general partner of Canada V GP. The Reporting Person, a member of the Issuer's board of directors, is a director of Canada V GP-GP and may be deemed to share voting and dispositive power over the shares held by Canada V. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.
F4 Shares are held by Versant Ophthalmic Affiliates Fund I, L.P. ("Ophthalmic"). Versant V GP is the sole general partner of Ophthalmic. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Ophthalmic. The Reporting Person disclaims beneficial ownership of the shares held by Ophthalmic, except to the extent of his respective pecuniary interest therein.
F5 Shares are held by Versant Affiliates Fund V, L.P. ("Affiliates V"). Versant V GP is the sole general partner of Affiliates V. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Versant V GP and may be deemed to share voting and dispositive power over the shares held by Affiliates V. The Reporting Person disclaims beneficial ownership of the shares held by Affiliates, except to the extent of his respective pecuniary interest therein.
F6 Shares held by Versant Vantage II, L.P. ("Vantage II"). Versant Vantage II GP, L.P. ("Vantage II GP") is the sole general partner of Vantage II and Versant Vantage II GP-GP, LLC (Vantage II GP-GP") is the sole general partner of Vantage II GP. The Reporting Person, a member of the Issuer's board of directors, is a managing director of Vantage II GP-GP and may be deemed to share voting and dispositive power over the shares held by Vantage II. The Reporting Person disclaims beneficial ownership of the shares held by Canada V, except to the extent of his respective pecuniary interest therein.